2022年4月1日
Pleryon Therapeutics (Shenzhen) Ltd. (“Pleryon”) is pleased to announce the completion of closed to 100 million RMB in Pre-A round financing. This round was led by Lapam Investment, with participation from Kaitai Capital and existing shareholder Zero2IPO Venture.
Pleryon is dedicated to developing innovative pharmaceutical products based on advanced polymer and drug delivery systems. The company’s core team members have over 20 years of research and development experience in biomaterials and drug delivery, having previously worked at renowned universities and multinational pharmaceutical companies both domestically and internationally. Pleryon employs a multidisciplinary and multi-platform strategy to regulate pharmaceutical products at both temporal and spatial scales. The funds from this round of financing will support Pleryon’s pre-clinical development in existing innovative pipelines, particularly in ophthalmology and orthopedics, and accelerate the construction of subsequent research and development pipelines based on their technological platform.
Dr. Yu Yu, founder of Pleryon, stated:
“We are honored to receive recognition from investors such as Lapam Investment and Kaitai Capital, who have long focused on early-stage investments in biotech. We will take this opportunity to accelerate pipeline development and further enhance our company’s structure and team.”
Mr. Zhihua Yu, founding partner of Lapam Investment, commented:
“Polymer therapeutics and drug delivery systems are a highly promising direction for innovative drug development. Pleryon Therapeutics is leveraging the academic research achievements of its core founding team for industrial development. With a diversified platform and scalable product pipeline, the company has enormous market potential. We look forward to seeing Pleryon’s products applied in clinical settings soon, benefiting more patients.”
About Pleryon:
Pleryon is dedicated to developing innovative pharmaceutical products based on polymer and drug delivery systems and has research centers in Shenzhen and Shanghai. For more information, please visit www.pleryon.com.
About Lapam Investment:
Lapam Investment, headquartered in Beijing, is a leading biopharmaceutical venture capital firm in China. Currently, Lapam Investment manages four RMB funds and one USD fund, with a total scale exceeding 6 billion RMB. It is the only biopharmaceutical special fund funded by the National Social Security Fund. Lapam Investment focuses on high-quality projects in the field of innovative drugs and medical devices, primarily investing in early-stage and mid-stage startups. They have invested in over 50 innovative drug companies and more than 10 innovative medical device companies, including well-known projects such as Betta Pharma, Remegen Co., Ltd, Clover Biopharmaceuticals, Asieris Pharmaceuticals, Stemirna Therapeutics, Binhui Bio, ImmuneOnco, Biostar Pharma, and Eyebright Medical. The Lapam Investment management team includes several partners with over 20 years of international/domestic experience in biopharmaceutical R&D and management, providing comprehensive value-added services to invested companies.
About Kaitai Capital:
Kaitai Capital is an innovative capital management institution that focuses on investments in biopharmaceuticals and life sciences, artificial intelligence and digital technology, and data intelligence and technology consumables. In the field of biopharmaceuticals and life sciences, Kaitai Capital has a global perspective, forward-looking industry research, and an ecosystem-investment concept. They have invested in over 100 domestic and foreign biopharmaceutical and life science companies, forming a collaborative industry ecosystem. Their investment portfolio covers areas such as oncology, autoimmune diseases, metabolic diseases, anti-infection, respiratory diseases, cardiovascular diseases, neuroscience, kidney diseases, ophthalmology, dermatology, gene therapy, cell therapy, innovative biotechnology, and the broader healthcare industry.
About Zero2IPO Venture:
Zero2IPO Venture is an investment platform under Zero2IPO Group. Founded in 2000, Zero2IPO Group is a leading comprehensive service provider for entrepreneurship and investment in China. The group operates two main business models: Zero2IPO Entrepreneurship and Zero2IPO Investment, driving strategic equity investment in the capital market. Zero2IPO Venture was established in 2006 and has managed 11 RMB funds and 4 USD funds, investing in nearly 200 outstanding enterprises. They primarily focus on investment opportunities in hard technology, medical devices and services, new consumption, and enterprise services, aiming to discover and invest in early-stage high-growth potential companies.